Clinical trial
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
NCT00966277
Study timeline
Study start (unknown)2010-04-01Date precision: month
Registry last updated2016-12-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Pancreatic Cancerunresolved
Venous Thromboembolismunresolved
Interventions
DalteparinDRUG · verified · RxNorm: dalteparin
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
Eisai Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00966277 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.